[go: up one dir, main page]

WO2013048153A3 - 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자 - Google Patents

인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자 Download PDF

Info

Publication number
WO2013048153A3
WO2013048153A3 PCT/KR2012/007835 KR2012007835W WO2013048153A3 WO 2013048153 A3 WO2013048153 A3 WO 2013048153A3 KR 2012007835 W KR2012007835 W KR 2012007835W WO 2013048153 A3 WO2013048153 A3 WO 2013048153A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
influenza
binding molecule
neutralizing activity
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/007835
Other languages
English (en)
French (fr)
Other versions
WO2013048153A2 (ko
Inventor
장신재
권기성
이계숙
이현주
전재원
전황근
장민석
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltrion Inc
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES12835569.0T priority Critical patent/ES2641257T3/es
Priority to JP2014533206A priority patent/JP5998222B2/ja
Priority to MX2014003745A priority patent/MX350282B/es
Priority to US14/348,284 priority patent/US9475861B2/en
Priority to EA201400274A priority patent/EA026527B1/ru
Priority to CN201280047234.0A priority patent/CN104011077B/zh
Priority to AU2012316930A priority patent/AU2012316930B2/en
Priority to EP12835569.0A priority patent/EP2762491B1/en
Application filed by Celltrion Inc filed Critical Celltrion Inc
Priority to CA2850720A priority patent/CA2850720C/en
Publication of WO2013048153A2 publication Critical patent/WO2013048153A2/ko
Publication of WO2013048153A3 publication Critical patent/WO2013048153A3/ko
Priority to IL231779A priority patent/IL231779B/en
Anticipated expiration legal-status Critical
Priority to US15/259,823 priority patent/US9856312B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)

Abstract

본 발명은 인간 B 세포에서 생산된 인플루엔자 A 바이러스 중화 활성을 가진 결합 분자에 관한 것으로, 본 발명의 인플루엔자 A 바이러스에 중화 활성을 가지는 결합 분자는 인플루엔자 A 바이러스에 감염된 환자의 혈액에서 선별된 B 세포에서 생산하는 결합 분자로서 인플루엔자 A 바이러스 대하여 중화 활성을 가지고 있으므로 인플루엔자 A 바이러스 유래 질환의 예방 및 치료에 유용하며, 본 발명의 결합 분자를 이용하여 인플루엔자 A 바이러스의 진단에도 유용하게 이용될 수 있다.
PCT/KR2012/007835 2011-09-30 2012-09-27 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자 Ceased WO2013048153A2 (ko)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2012316930A AU2012316930B2 (en) 2011-09-30 2012-09-27 Binding molecule having influenza A virus-neutralizing activity produced from human B cell
MX2014003745A MX350282B (es) 2011-09-30 2012-09-27 Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
US14/348,284 US9475861B2 (en) 2011-09-30 2012-09-27 Binding molecule having influenza A virus-neutralizing activity produced from human B cell
EA201400274A EA026527B1 (ru) 2011-09-30 2012-09-27 Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека
CN201280047234.0A CN104011077B (zh) 2011-09-30 2012-09-27 从人b细胞产生的具有甲型流感病毒中和活性的结合分子
EP12835569.0A EP2762491B1 (en) 2011-09-30 2012-09-27 Binding molecule having influenza a virus-neutralizing activity produced from human b cell
CA2850720A CA2850720C (en) 2011-09-30 2012-09-27 Binding molecule having influenza a virus-neutralizing activity produced from human b cell
ES12835569.0T ES2641257T3 (es) 2011-09-30 2012-09-27 Molécula de unión que tiene actividad neutralizadora contra el virus de la influenza A producida a partir de células B humanas
JP2014533206A JP5998222B2 (ja) 2011-09-30 2012-09-27 ヒトｂ細胞で生産されたインフルエンザａウイルス中和活性を持つ結合分子
IL231779A IL231779B (en) 2011-09-30 2014-03-27 A binding molecule with neutralizing activity for type a influenza virus produced from a type b human cell
US15/259,823 US9856312B2 (en) 2011-09-30 2016-09-08 Binding molecule having influenza A virus-neutralizing activity produced from human B cell

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110099646 2011-09-30
KR10-2011-0099646 2011-09-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/348,284 A-371-Of-International US9475861B2 (en) 2011-09-30 2012-09-27 Binding molecule having influenza A virus-neutralizing activity produced from human B cell
US15/259,823 Continuation US9856312B2 (en) 2011-09-30 2016-09-08 Binding molecule having influenza A virus-neutralizing activity produced from human B cell

Publications (2)

Publication Number Publication Date
WO2013048153A2 WO2013048153A2 (ko) 2013-04-04
WO2013048153A3 true WO2013048153A3 (ko) 2013-05-23

Family

ID=47996632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/007835 Ceased WO2013048153A2 (ko) 2011-09-30 2012-09-27 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자

Country Status (12)

Country Link
US (2) US9475861B2 (ko)
EP (1) EP2762491B1 (ko)
JP (1) JP5998222B2 (ko)
KR (1) KR101514682B1 (ko)
CN (1) CN104011077B (ko)
AU (1) AU2012316930B2 (ko)
CA (2) CA2850720C (ko)
EA (1) EA026527B1 (ko)
ES (1) ES2641257T3 (ko)
IL (1) IL231779B (ko)
MX (1) MX350282B (ko)
WO (1) WO2013048153A2 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN110642944B (zh) * 2014-03-07 2021-06-11 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
JPWO2016010160A1 (ja) * 2014-07-18 2017-06-01 国立感染症研究所長 抗インフルエンザウイルス抗体及びその利用
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
WO2016089181A1 (ko) * 2014-12-05 2016-06-09 (주)셀트리온 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물
US11135282B2 (en) * 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
JP6638913B2 (ja) * 2016-04-21 2020-02-05 国立大学法人大阪大学 生体物質検出用デバイス、生体物質検出用検出装置、イオン電流の測定方法、及び、生体物質の識別方法
CN109803640B (zh) * 2016-08-10 2022-01-04 赛特瑞恩股份有限公司 稳定的液体抗流感病毒抗体医药调配物
KR102320280B1 (ko) * 2018-05-31 2021-11-29 주식회사 센트릭스바이오 CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
KR20200060969A (ko) 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
KR20110102198A (ko) * 2010-03-08 2011-09-16 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 인간 단일클론 항체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637837A1 (en) 2006-01-26 2007-08-09 Hx Diagnostics, Inc. Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
US8148085B2 (en) * 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
CA2719201A1 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
JP2012526839A (ja) * 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
JP6210685B2 (ja) * 2010-01-27 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
EP2596017B1 (en) * 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
WO2012096994A2 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
KR20110102198A (ko) * 2010-03-08 2011-09-16 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 인간 단일클론 항체

Also Published As

Publication number Publication date
IL231779B (en) 2019-01-31
KR101514682B1 (ko) 2015-04-23
JP5998222B2 (ja) 2016-09-28
JP2014530008A (ja) 2014-11-17
ES2641257T3 (es) 2017-11-08
CA2850720C (en) 2016-03-29
KR20130035916A (ko) 2013-04-09
EP2762491A2 (en) 2014-08-06
EA026527B1 (ru) 2017-04-28
MX350282B (es) 2017-09-01
CN104011077B (zh) 2017-06-20
EA201400274A1 (ru) 2014-09-30
EP2762491B1 (en) 2017-07-05
EP2762491A4 (en) 2015-05-20
IL231779A0 (en) 2014-05-28
US20140234336A1 (en) 2014-08-21
AU2012316930A1 (en) 2014-04-17
CN104011077A (zh) 2014-08-27
US9475861B2 (en) 2016-10-25
CA2900712A1 (en) 2013-04-04
US20170037113A1 (en) 2017-02-09
MX2014003745A (es) 2014-07-22
CA2850720A1 (en) 2013-04-04
WO2013048153A2 (ko) 2013-04-04
US9856312B2 (en) 2018-01-02
AU2012316930B2 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
WO2013048153A3 (ko) 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
WO2011111966A3 (en) Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
WO2014159822A3 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
EP3042910A3 (en) 2'-spiro-nucleosides for use in the therapy of hepatitis c
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
PH12014501702A1 (en) Imidazopyrrolidinone compounds
UY34918A (es) Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso
WO2011000566A3 (en) Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
MY166282A (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
WO2011076367A3 (en) Synergistic antiviral composition and use thereof
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA201300132A1 (ru) Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич
IL220318A (en) Aqueous solutions comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart diseases
WO2013124807A3 (en) Oligonucleotides for modulating gene expression and uses thereof
IL232393A0 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids
WO2015086738A3 (en) Hiv vaccine
WO2014025749A3 (en) Small molecule inhibitors of viral protein interactions with human t-rna
UA108975C2 (uk) Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями
MX2010000120A (es) Estereoisomeros de triciclodecan-9-il-xantogenato.
WO2014065848A3 (en) Compounds for treating papilloma virus infection
UA104484C2 (uk) Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201400274

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 231779

Country of ref document: IL

Ref document number: MX/A/2014/003745

Country of ref document: MX

REEP Request for entry into the european phase

Ref document number: 2012835569

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14348284

Country of ref document: US

Ref document number: 2012835569

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014533206

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2850720

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012316930

Country of ref document: AU

Date of ref document: 20120927

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12835569

Country of ref document: EP

Kind code of ref document: A2